Cosmetovigilancia: un estudio de alcance

Los cosméticos son productos de venta libre y de uso diario para los consumidores,quienes restan importancia a las implicaciones de salud que pueden experimentara causa de los mismos. Es necesario monitorear la postcomercialización de estosproductos, ya que en los años recientes se han visto asociados a reacciones adversas;de esta manera nace el concepto de cosmetovigilancia y la necesidad de implementarsistemas para llevarla a cabo. Esta revisión sistemática encontró un limitado númerode publicaciones que informen del estado actual y de las tendencias de la cosmetovigilancia, aunque fue posible definir el concepto e identificar los paísesque lo han desarrollado e implementado, siendo la Unión Europea quien lidera estos aspectos, contando con la participación de distribuidores, industrias, profesionales de la salud y consumidores.La cosmetovigilancia es un campo de la vigilancia sanitaria que se encuentra aún en desarrollo y por lo tanto, es importante continuar con la indagación al respecto,hasta lograr un mecanismo de vigilancia eficiente y útil tanto para los países miembros de la Unión Europea, como para aquellos que aún se encuentran en vías de desarrollo, como Colombia.Cosmetics are free sale products that are used daily by consumers who usually not concerned about the possible health implications by the use of these products. It is necessary to perform a post-sale monitoring for these products, since in recent years they have been associated with adverse reactions. For this reason was built the cosmetovigilance concept as well as the need to implement a system to perform this task. This systematic review found a limited number of publications about the current cosmetovigilance status and tendencies at world level. Nevertheless, it was possible to define the concept and identify the countries that have developed and implemented this system. European Union is the leader in this topic, with investigations, regulations, development and implementation of an harmonized cosmetovigilance system. These activities include the participation of distributors, manufacturing industries, health professionals and consumers. Cosmetovigilance is a sanitary vigilance area that is still under development and therefore it is important to keep on investigating about this topic until achieve an efficient and useful system, for both European Union members and developing countries such as Colombia

Cosmetovigilancia: un estudio de alcance

Los cosméticos son productos de venta libre y de uso diario para los consumidores,quienes restan importancia a las implicaciones de salud que pueden experimentara causa de los mismos. Es necesario monitorear la postcomercialización de estosproductos, ya que en los años recientes se han visto asociados a reacciones adversas;de esta manera nace el concepto de cosmetovigilancia y la necesidad de implementarsistemas para llevarla a cabo. Esta revisión sistemática encontró un limitado númerode publicaciones que informen del estado actual y de las tendencias de la cosmetovigilancia, aunque fue posible definir el concepto e identificar los paísesque lo han desarrollado e implementado, siendo la Unión Europea quien lidera estos aspectos, contando con la participación de distribuidores, industrias, profesionales de la salud y consumidores.La cosmetovigilancia es un campo de la vigilancia sanitaria que se encuentra aún en desarrollo y por lo tanto, es importante continuar con la indagación al respecto,hasta lograr un mecanismo de vigilancia eficiente y útil tanto para los países miembros de la Unión Europea, como para aquellos que aún se encuentran en vías de desarrollo, como Colombia.Cosmetics are free sale products that are used daily by consumers who usually not concerned about the possible health implications by the use of these products. It is necessary to perform a post-sale monitoring for these products, since in recent years they have been associated with adverse reactions. For this reason was built the cosmetovigilance concept as well as the need to implement a system to perform this task. This systematic review found a limited number of publications about the current cosmetovigilance status and tendencies at world level. Nevertheless, it was possible to define the concept and identify the countries that have developed and implemented this system. European Union is the leader in this topic, with investigations, regulations, development and implementation of an harmonized cosmetovigilance system. These activities include the participation of distributors, manufacturing industries, health professionals and consumers. Cosmetovigilance is a sanitary vigilance area that is still under development and therefore it is important to keep on investigating about this topic until achieve an efficient and useful system, for both European Union members and developing countries such as Colombia

The Eleventh and Twelfth Data Releases of the Sloan Digital Sky Survey: Final Data from SDSS-III

The third generation of the Sloan Digital Sky Survey (SDSS-III) took data from 2008 to 2014 using the original SDSS wide-field imager, the original and an upgraded multi-object fiber-fed optical spectrograph, a new near-infrared high-resolution spectrograph, and a novel optical interferometer. All of the data from SDSS-III are now made public. In particular, this paper describes Data Release 11 (DR11) including all data acquired through 2013 July, and Data Release 12 (DR12) adding data acquired through 2014 July (including all data included in previous data releases), marking the end of SDSS-III observing. Relative to our previous public release (DR10), DR12 adds one million new spectra of galaxies and quasars from the Baryon Oscillation Spectroscopic Survey (BOSS) over an additional 3000 deg2 of sky, more than triples the number of H-band spectra of stars as part of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE), and includes repeated accurate radial velocity measurements of 5500 stars from the Multi-object APO Radial Velocity Exoplanet Large-area Survey (MARVELS). The APOGEE outputs now include the measured abundances of 15 different elements for each star. In total, SDSS-III added 5200 deg2 of ugriz imaging; 155,520 spectra of 138,099 stars as part of the Sloan Exploration of Galactic Understanding and Evolution 2 (SEGUE-2) survey; 2,497,484 BOSS spectra of 1,372,737 galaxies, 294,512 quasars, and 247,216 stars over 9376 deg2; 618,080 APOGEE spectra of 156,593 stars; and 197,040 MARVELS spectra of 5513 stars. Since its first light in 1998, SDSS has imaged over 1/3 of the Celestial sphere in five bands and obtained over five million astronomical spectra. \ua9 2015. The American Astronomical Society

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection